Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to regrow hair in severe alopecia

NCT ID NCT06060977

Disease control Sponsor: Inmagene LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a drug called IMG-007 in 29 adults with alopecia areata who had lost at least half of their scalp hair. The main goal was to check safety, but researchers also measured hair regrowth using a standard tool. The study is now complete, and results will help decide if larger trials are warranted.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
IMG-007 (intravenous infusion)
What this could lead to
If successful, this could point toward a new treatment option for people with significant hair loss from alopecia areata.
What could go wrong
This is an early-phase trial with only 29 participants, so results may not apply to everyone. The drug may not prove effective or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

29 people

The number who actually took part.

Started

Sep 2023

Finished

Jan 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Male or female aged ≥ 18 and ≤ 65 years * AA with current episode of hair loss of \> 6 months but \< 8 years * AA with ≥ 50% scalp involvement as defined as SALT score ≥ 50 Key Exclusion Criteria: * Known hepatitis B, hepatitis C, or human immunodeficiency virus infection * Evidence of active or latent tuberculosis (TB) * History of untreated or inadequately treated TB infection. * Active infection requiring treatment with systemic antibiotics, antivirals, antifungals, antiparasitics or antiprotozoals at the Screening visit * Concurrent hair loss due to other etiologies * Primary "diffuse" type of AA * Active inflammatory diseases on the scalp that would interfere with the assessment of AA * History or presence of hair transplants or micropigmentation of the scalp * Active systemic diseases that may cause hair loss * Other conditions or laboratory abnormality that could increase the risk associated with study participation or could interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alopecia areata(AA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alopecia alopecia areata immune system disorder skin disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alopecia areata(AA)

Contacts and locations

Locations

  • Alliance Clinical Research of Tampa

    Tampa, Florida, 33615, United States

  • Centre de Recherche Saint-Louis

    Québec, Quebec, G1W4R4, Canada

  • Dawes Fretzin Clinical Resarch Group, LLC

    Indianapolis, Indiana, 47906, United States

  • Dermatology Specialists of Spokane

    Spokane, Washington, 99202, United States

  • Great Lakes Research Group Inc.

    Bay City, Michigan, 48706, United States

  • Guelph Dermatology Research

    Guelph, Ontario, N1L0B7, Canada

  • Innovaderm Research Inc.

    Montreal, Canada

  • Lahey Hospital & Medical Center

    Burlington, Massachusetts, 01803, United States

  • Northwest Arkansas Clinical Trials Center, PLLC/ Hull Dermatology P.A.

    Rogers, Arkansas, 72758, United States

  • Options Research Group

    West Lafayette, Indiana, 47906, United States

  • Research Toronto

    Toronto, Ontario, M2W2N4, Canada

  • SimcoMed Health Ltd.

    Barrie, Ontario, L4M7G1, Canada

  • Skin Cancer and Dermatology Institute

    Reno, Nevada, 89509, United States

  • Skin Health

    Cobourg, Ontario, K9A0Z4, Canada

  • Skin Search of Rochester, Inc.

    Rochester, New York, 14623, United States

  • Stride Clinical Research LLC

    Sugar Land, Texas, 77479, United States

  • Torrance Clinical Research Institute Inc.

    Lomita, California, 90717, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.